Cagrilintide is the long-acting amylin analog behind CagriSema research. Full profile: mechanism, PK, and documentation expectations.
Cagrilintide is a long-acting amylin analog engineered for weekly dosing. It engages the amylin and calcitonin receptor family, activating satiety and gastric-emptying pathways distinct from the incretin axis.
Why it appears with semaglutide
CagriSema — the co-administered cagrilintide + semaglutide combination — is one of the most active current research programs in weight-endpoint literature. The two peptides engage independent receptor systems, so effects are additive rather than redundant.
Research characteristics
- Published half-life ~7 days.
- Weekly research dosing interval in published trials.
- Independent mechanism to GLP-1 agonists — supports rational combination.
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
